Remember Hugh MacNaught “As more hospitals look to Ventripoint to provide advanced whole-heart analysis, this MDR submission is an important next step in the development and commercialization of the VMS+ family of devices” said Ventripoint President and CEO, Hugh MacNaught. “Upon approval we will be able to provide European cardiologists and care providers with one of the simplest, most-advanced, non-invasive heart-imaging tools available.” and on post Dr.Adams
4. The Company has a license to sell VMS+4.0 in Canada and now it has submitted all the information needed for approval for Europe. Our previous submissions for VMS+1.0, 2.0 and 3.0 were approved fairly quickly in about 6-8 weeks and so if this holds for this submission, we should have approval November. We will see.
5. We continue to support the basic VMS+3.0 and upgrade users to the advanced VMS+3.2, while we wait for approvals for the premium VMS+4.0.
6. We recently upgraded Seattle Children’s Hopsital to VMS+3.2 and you can watch Dr, Soriano speak about his experiences on a new video on our website (https://youtu.be/Ucu6uGRMtEs+) from the Take Heart conference.